pubmed:abstractText |
Cerebral malaria carries an unacceptable case fatality rate in children despite timely and adequate chemotherapy. To improve the survival rate, adjunctive therapies previously tested mainly focused on the modulation of the inflammatory response, without definitive effect in humans. In this context, a new adjunctive strategy using a neuroprotective drug: erythropoietin (epoietin-beta, Epo) was proposed.
|
pubmed:affiliation |
Malaria Research Unit, EA 4170, University Lyon 1, Faculty of Medicine, Lyon, France. picot@sante.univ-lyon1.fr
|